June 29th 2025
Results from Invivyd’s pemivibart (Pemgarda) phase 3 trial show it had a significant PrEP effect during the 6-month on-drug period for both immunocompromised and immunocompetent populations.
June 25th 2025
New epidemiologic data, vaccine effectiveness, and safety assessments guide a move from universal to targeted vaccination recommendations for the 2025–26 season.
June 12th 2025
Although COVID-19 has receded quite a bit from the minds of many, it still remains a virus that can present serious morbidity and mortality. Here is a review of clinical treatment strategies by an intensivist when seeing patients with severe COVID-19.
June 12th 2025
Phase 3 results show immune response and tolerability in adults 65 and older, following phase 2 findings.
May 31st 2025
The company's vaccine, mRNA-1283, becomes the first approval under the new federal guidelines.
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
A Shield of Protection: Unmet Needs in COVID-19 Prevention and Control
October 7, 2025
Register Now!
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
View More
Addressing Racial Disparities in Multiple Myeloma: Forging a Path Towards Health Equity in Clinical Trials and Everyday Practice
View More
Health Care Workers Hospitalized with COVID-19 May Have Lower Risks
February 8th 2021Health care workers hospitalized with COVID-19 showed no greater risk than the general public for mechanical ventilation or death, and may actually have less risk of ICU admission and shorter hospital stays, a new study found.
Read More
Social Disadvantages Associated with Higher Rates of COVID-19 Cases, Death
February 5th 2021US counties that scored higher on the Social Vulnerability Index, which includes such factors as poverty, unemployment and education, saw higher incidence rates of COVID-19 cases and deaths, a University of Michigan study found.
Read More
FDA Updates its EUA for Convalescent Plasma
February 5th 2021The agency limited it Emergency Use Authorization (EUA) for the COVID-19 therapy to the use of high titer COVID-19 convalescent plasma only for the treatment of hospitalized patients early in the disease. FDA is no longer authorizing the use of low-titer plasma in its EUA due to a lack of efficaciousness in further studies.
Read More
Potential Disruptions in HIV, TB, and Malaria Response due to COVID-19
February 1st 2021Concerns are being raised for COVID-19 and the potential impact on HIV, tuberculosis, and malaria in low-income and middle-income countries. A team of researchers recently addressed this issue with a modeling study.
Read More
2 Commerce Drive
Cranbury, NJ 08512